Premium
Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low‐dose cyclophosphamide and anti‐thymocyte globulin
Author(s) -
Ayas M.,
AlMusa A.,
AlJefri A.,
AlSeraihi A.,
AlMahr M.,
Rifai S.,
ElSolh H.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20696
Subject(s) - dyskeratosis congenita , medicine , cyclophosphamide , regimen , bone marrow failure , anti thymocyte globulin , conditioning regimen , transplantation , stem cell , oncology , gastroenterology , chemotherapy , haematopoiesis , dna , genetics , telomere , biology
Abstract Bone marrow failure is the major cause of early mortality in patients with dyskeratosis congenita (DC); early trials with conventional conditioning regimens were associated with remarkable chronic morbidity and mortality, and the optimal conditioning regimen for these patients remains undetermined. We report a case of a child afflicted with DC who underwent related full HLA‐matched stem cell transplant (SCT) using a regimen of low dose cyclophosphamide and antithymocyte globulin (ATG). The regimen was well tolerated and associated with no significant short‐term toxicity. Pediatr Blood Cancer 2007;49:103–104. © 2005 Wiley‐Liss, Inc.